AstraZeneca shares slid on Monday despite positive news from the drugmaker’s first human trials of an experimental COVID-19 vaccine.
In the early-stage trial of the vaccine, which is being developed in conjunction with Oxford University, healthy volunteers generated immune responses.
In early US trading, the company’s stock was down by about 2.7%.
Watch AstraZeneca trade live on Markets Insider.
Visit Business Insider’s homepage for more stories.

AstraZeneca shares fell on Monday even after the publication of positive results from a trial of its experimental COVID-19 vaccine developed in partnership with Oxford University.

The study, published in The Lancet on Monday, said healthy volunteers who received the experimental vaccine, called AZD1222, showed immune responses.See the rest of the story at Business Insider

NOW WATCH: How waste is dealt with on the world’s largest cruise ship

See Also:

US weekly jobless claims hit 1.3 million, slightly exceeding economist forecastsGlobal consumer confidence posted a record plunge in the 2nd quarter as the coronavirus pandemic slammed job prospects, financesBANK OF AMERICA: Buy these 7 pharma stocks now as they race to develop COVID-19 treatments and vaccines

SEE ALSO: The EU is deadlocked over its proposed $860 billion coronavirus rescue package, as a group of ‘frugal’ nations stall talks

Original Source: